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Hepatitis E virus (HEV) is a positive-strand RNA virus that is prevalent in much of the developing world.
ORF2 is the major capsid protein of HEV. Although ORF2 is an N-linked glycoprotein, it is abundantly located
in the cytoplasm in addition to having membrane and surface localization. The mechanism by which ORF2
protein obtains access to the cytoplasm is unknown. In this report, we prove that initially all ORF2 protein is
present in the endoplasmic reticulum and a fraction of it becomes retrotranslocated to the cytoplasm. The
ability of ORF2 to be retrotranslocated is dependent on its glycosylation status and follows the canonical
dislocation pathway. However, in contrast to general substrates of the dislocation pathway, retrotranslocated
ORF2 protein is not a substrate of the 26S proteasome complex and is readily detectable in the cytoplasm in
the absence of any protease inhibitor, suggesting that the retrotranslocated protein is stable in the cytoplasm.
This study thus defines the pathway by which ORF2 obtains access to the cytoplasm.
Cells are equipped with various checkpoints and quality con-
trol mechanisms to maintain proper homeostasis, which is es-
sential for their survival and proliferation. One of the most
critical quality control mechanisms operates in the endoplas-
mic reticulum (ER); this mechanism ensures that nascent pro-
teins are properly folded and only proteins with a biologically
active conformation are allowed to move beyond the ER (2).
Improperly folded or unassembled proteins are retrotranslo-
cated from the ER and degraded by a process called ER-
associated degradation (ERAD) (20). This mechanism also
helps the cell alleviate ER overload in case of viral infection,
whereby expression of viral proteins creates an extra burden
over the cell organelle (6). Pathogens too have evolved strat-
egies to exploit the retrotranslocation pathway to degrade host
molecules in order to create a favorable environment for them.
For example, the US11 gene product of human cytomegalovi-
rus virus induces ERAD of major histocompatibility complex
class I molecules to evade the host immune response (19). The
retrotranslocation pathway has also been used by toxic proteins
of several extracellular pathogens to gain access to the cytosol.
Notable examples of these are cholera toxin, ricin, and AB
toxins (3, 11, 16). Once in the cytosol, these proteins play
strategic roles to further interfere with the cellular machinery.
Hepatitis E virus (HEV) is the causative agent of viral hep-
atitis, which is a major concern for much of the developing
world. The virus carries a positive-strand RNA as its genome,
which carries three known open reading frames (ORFs). While
ORF1 codes for nonstructural proteins essential for viral rep-
lication, ORF2 codes for the major capsid protein which is
predicted to encapsulate the genome, and ORF3 codes for a
small phosphoprotein whose in vivo function is yet to be de-
fined. However, in cell culture-based assays, it has been shown
to perturb various cellular signaling intermediates, such as
inhibiting mitogen-activated protein kinase (MAPK) activity
(5, 7), and it enhances the secretion of an immunosuppressant
called 1-microglobulin (14, 18).
ORF2 is an N-linked glycoprotein which is cotranslationally
translocated into the ER (23). It is glycosylated at three amino
acid residues, as judged by mutational analysis. A fraction of it
is also observed on the cell surface. Despite being cotransla-
tionally translocated into the ER, ORF2 has been found to
exist as both glycosylated and nonglycosylated forms in the
total cell lysate, and a significant fraction of it is also observed
in the cytoplasm (15). The mechanism behind this phenome-
non remains unknown.
In this article, we describe the pathway by which ORF2
protein localizes to the cytoplasm. Heterologous expression of
ORF2 protein results in its accumulation in the ER initially.
Gradually, a fraction of this protein is translocated back to the
cytoplasm. This retrotranslocation could be blocked by treat-
ment of cells with various biochemical and genetic inhibitors of
the ER-associated degradation pathway, thus suggesting that it
may be a canonical ERAD substrate. However, ORF2 protein
is not a substrate of the 26S proteasome. Rather, retrotrans-
located ORF2 protein is stable in the cytoplasm, indicating that
it mimics an ERAD substrate to get access to the cytoplasm. In
addition, the protein levels of several ER stress-regulated
chaperones were found to be upregulated, suggesting that ER
stress was induced in ORF2-expressing cells.
MATERIALS AND METHODS
Plasmids and reagents. Cloning of pSGI ORF2 and pSGI 35 ORF2 has been
described earlier (4, 23). pSGI KDEL ORF2 was prepared by modifying the
native C-terminal sequence of ORF2, KTREL, to KDEL by site-directed mu-
tagenesis. The clone was verified by sequencing. Wild-type and ATPase-dead p97
expression constructs (pCDNA 3.1 vector) (21) were gifts from T. A. Rapoport.
All the DNA constructs used for mammalian cell transfection were purified by
cesium chloride gradient centrifugation (10). All antibodies except those for
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ORF2 and ORF3 were purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). ORF2 and ORF3 antibodies were raised in our laboratory and have
been described earlier (4). MG132 and kifunensine were purchased from Cal-
biochem Chemicals (San Diego, CA). Tunicamycin, cycloheximide, NH4Cl, and
monensin were from Sigma-Aldrich (St. Louis, MO).
Cell culture and transfection. Huh7 cells were maintained in Dulbecco mod-
ified Eagle medium (DMEM) supplemented with penicillin, streptomycin, and
10% fetal bovine serum. Cells were transfected with Lipofectin/Lipofectamine
2000 reagent (Invitrogen Corp., Carlsbad, CA) as per the manufacturer’s instruc-
tions. For mock transfection, cells were transfected with the respective empty
vectors.
Metabolic labeling, immunoprecipitation, and immunoblotting. Radiolabeling
of cells with [35S]Cys/Met promix, immunoprecipitation, and immunoblotting
were done as described by Surjit et al. (13). The data reported are representative
of at least three independent sets of experiments conducted. All the inhibitors
were added during the starvation period and maintained throughout the labeling
period. The effective concentration of the different inhibitors are as follows:
MG132, 50 M; cycloheximide, 100 g/ml; tunicamycin, 10 g/ml; monensin, 5
M; NH4Cl, 30 mM; and kifunensine, 0.2 mM.
Pulse-chase assay. At 44 h posttransfection, cells transfected in 60-mm culture
dishes were pulse-labeled for 20 min with 250 Ci of [35S]Cys/Met labeling mix
mixed with 1 ml Cys/Met-deficient DMEM and chased in complete medium
(DMEM containing Cys/Met and serum) for the indicated time periods, followed
by immunoprecipitation, as described by Surjit et al. (12). The approximate cell
density at the time of labeling was 85 to 90%.
Membrane fractionation. Cytoplasmic proteins were separated from the mem-
brane fraction by digitonin permeabilization of the plasma membrane as de-
scribed by Afshar et al. (1). Membrane fractionation by ultracentrifugation was
done as described by Surjit et al. (12).
RESULTS
A fraction of the ORF2 protein is retrotranslocated from the
ER to the cytoplasm. In an attempt to understand the mech-
anism of the intracellular distribution of the ORF2 protein, we
systematically checked its appearance in the cytoplasmic frac-
tion after entry into the ER. There are two possible ways for an
N-linked glycoprotein to gain access to the cytoplasm: (i) by
direct retrotranslocation from the ER to the cytoplasm or (ii)
through retrograde transport from the cell surface. To test the
first possibility, we blocked protein transport to the cell surface
by treating cells with monensin, pulse-labeled the ORF2 pro-
tein with [35S]Cys/Met promix, separated cytoplasmic and
membrane fractions from the cell lysate, and examined each
fraction for the presence of the ORF2 protein at different time
points. Cytoplasmic proteins were released from the cells by
permeabilizing the plasma membrane with digitonin, which has
earlier been proved to maintain the integrity of the ER mem-
brane (1). As seen in Fig. 1A, at time zero of chase, the
membrane fraction contained two bands specific to the ORF2
protein, which correspond to glycosylated and nonglycosylated
types of ORF2 protein. No ORF2 protein was detected in the
cytoplasm at that time point. However, ORF2 presence in the
cytoplasm gradually increased with time (compare 2 h to 4 h;
Fig. 1A, lanes 6 to 8). These cells were also treated with
monensin to block anterograde transport beyond the Golgi.
This experiment indicated that initially all ORF2 protein is
translocated to the ER compartment and a fraction of it is
retrotranslocated back to the cytoplasm. Cross contamination
between ER and cytoplasm fractions was ruled out by immu-
noprecipitating aliquots of cell lysate with antibodies to cal-
nexin and protein disulfide isomerase (PDI), which are known
to be membrane associated and soluble ER resident proteins,
respectively (Fig. 1B). Next, we checked whether ORF2 is able
to retrotranslocate in the presence of other viral proteins. For
this, we coexpressed ORF2 along with ORF3 protein, which is
a small phosphoprotein produced by hepatitis E virus. These
cells were pulse-labeled for 20 min, followed by a 2-h chase in
complete medium and immunoprecipitation of ORF2 from the
membrane and cytoplasmic fractions. As expected, a fraction
of ORF2 protein was detected in the cytoplasmic fraction after
the 2-h chase period (Fig. 1C). Expression of ORF3 protein in
these samples was verified by immunoprecipitating an aliquot
of the sample with anti-ORF3 antibody (Fig. 1D).
The ability of the ORF2 protein to retrotranslocate from the
ER was further verified by using a different approach to sep-
arate cytoplasmic and membrane fractions, i.e., separating
both fractions by ultracentrifugation. In addition to monensin-
treated wild-type ORF2-expressing cells, we also simulta-
neously processed KDEL-ORF2-expressing cells to further en-
FIG. 1. A fraction of the ORF2 protein is retrotranslocated from
the ER to the cytoplasm. (A) Full-length ORF2-expressing cells were
treated with monensin, pulse-labeled for 20 min with [35S]cysteine/
methionine labeling mix, and harvested (lanes 1 to 4) or chased for 2
or 4 h in complete medium (lane 5 to 8). Cytoplasmic (C) and mem-
brane (M) fractions were separated by digitonin permeabilization and
immunoprecipitated with preimmune serum (lanes 1 and 2) or anti-
ORF2 antibody (lane 3 to 8), and radioactive bands were visualized by
fluorography. The star indicates a nonspecific band present in all
samples. Block arrows indicate the ORF2 band in the cytoplasm frac-
tion, and line arrows indicate ORF2 bands (glycosylated [gORF2] and
nonglycosylated [ORF2]). (B) ORF2-expressing (lanes 1 and 2) or
mock (lanes 3 and 4) cell lysates processed simultaneously and immu-
noprecipitated with anticalnexin (upper panel) or anti-PDI (lower
panel) antibody. (C) Huh7 cells cotransfected with full-length ORF2
and ORF3 expression plasmids were treated with monensin, pulse-
labeled for 20 min with [35S]cysteine/methionine labeling mix, and
harvested (lanes 1 and 2) or chased for 2 h in complete medium (lanes
3 and 4). Cytoplasmic and membrane fractions were separated by
digitonin permeabilization and immunoprecipitated with anti-ORF2
antibody, and bands were detected as described above. (D) Huh7 cells
cotransfected with full-length ORF2 and ORF3 expression plasmids
were treated with monensin, pulse-labeled for 20 min with [35S]cys-
teine/methionine labeling mix, harvested, and immunoprecipitated
with preimmune serum (PS) (lane 1) or anti-ORF3 antibody (lane 2).
Samples were resolved in 15% sodium dodecyl sulfate-polyacrylamide
gels and bands detected by fluorography.
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sure that anterograde trafficking of ORF2 is blocked. KDEL
signature residues are frequently present at the C termini of
many ER resident proteins, which are responsible for their ER
retention. We modified the KTREL sequence present at the C
terminus of ORF2 protein to KDEL to ensure that this protein
does not move beyond the ER by the anterograde transport
pathway (data not shown). Thus, by using this mutant, we
would be able to further confirm that any ORF2 protein de-
tectable in the cytoplasm comes directly from the ER compart-
ment and not through any other pathway. This experiment
revealed identical results (Fig. 2A), whereby both wild-type
and KDEL-ORF2 proteins appeared in the cytoplasmic frac-
tion after the 2-h chase period. Corresponding controls were
used to rule out the possibility of cross contamination (Fig.
2B). Further, to prove that the ORF2 protein present in the
membrane fraction actually represented the ORF2 protein
inside the ER compartment, we conducted a trypsin protection
assay. Aliquots of the membrane fraction of ORF2-expressing
cells were incubated with 100 g/ml trypsin for 30 min in either
the presence or absence of 0.5% NP-40. In the absence of
detergent, the ORF2 band could be detected, whereas in sam-
ples treated with detergent, no band or a very faint band
specific to ORF2 was detected (Fig. 2C). This proved that the
ORF2 protein present in the membrane fraction represents the
protein inside the ER compartment. Thus, it was clear that a
fraction of the ORF2 protein is directly translocated from the
ER to the cytoplasm.
In the normal course of events, retrotranslocated substrates
display a very short half-life in the cytoplasm since they are
very efficiently degraded by the 26S proteasome (17). However,
the ORF2 protein was stably present in the cytoplasm even
after a 4-h chase period. Hence, we subsequently designed
experiments to check whether ORF2 was a substrate of the 26S
proteasome. A pulse-chase assay revealed that, at 8 h of chase,
all the pulse-labeled ORF2 protein was completely degraded
(Fig. 3A). Next, we checked the effect of lysosomal (NH4Cl)
and proteasomal (MG132) inhibitors on the stability of the
ORF2 protein. At 8 h of chase, MG132 had no effect; however,
NH4Cl could stabilize approximately 60% of the total ORF2
protein (Fig. 3B). This suggested that ORF2 degradation was
independent of proteasomal activity. This observation was fur-
ther confirmed by checking for ubiquitination of the ORF2
protein. For this purpose, ORF2-expressing cells were treated
with MG132 for 3 h, followed by immunoprecipitation using
anti-ORF2 antibody and immunoblotting with antiubiquitin
antibody. We were unable to detect any ubiquitinated species
of the ORF2 protein (Fig. 3C). Thus, it was confirmed that the
ORF2 protein is not a proteasome substrate and hence that the
classical ERAD pathway is not responsible for its degradation.
ORF2 protein exploits the ERAD pathway to enter the cy-
toplasm. To gain further insight into the mechanism of retro-
translocation of the ORF2 protein, we utilized some known
biochemical and dominant negative inhibitors of the ERAD
pathway and monitored the appearance of ORF2 in the cyto-
plasmic fraction by pulse-chase analysis. We used two bio-
chemical inhibitors, tunicamycin and kifunensine. Tunicamycin
blocks N-linked glycosylation of proteins by inhibiting the
transfer of N-acetylglucosamine 1-phosphate to dolichol mono-
phosphate. Kifunensine is an inhibitor of ER mannosidase-1.
In a 2-h chase of the ORF2 protein in tunicamycin-treated
cells, no ORF2 protein was detected in the cytoplasmic frac-
tion, indicating that ORF2 dislocation was dependent on the
FIG. 2. A fraction of the ORF2 protein is retrotranslocated from the ER to the cytoplasm. (A) Full-length ORF2-expressing cells were
pulse-labeled for 20 min with [35S]cysteine/methionine labeling mix and harvested (lanes 1 and 2) or chased for 2 h in complete medium in the
presence (lanes 1, 2, 3, 4, 7, and 8) or absence (lanes 5 and 6) of monensin. Cytoplasmic (C) and membrane (M) fractions were separated by
ultracentrifugation and immunoprecipitated with anti-ORF2 antibody (lanes 1 to 6) or preimmune serum (lanes 7 and 8), and radioactive bands
were visualized by fluorography. The star indicates a nonspecific band present in all samples. Block arrows and line arrows indicate cytoplasmic
ORF2 and total ORF2 (both glycosylated [gORF2] and nonglycosylated) bands, respectively. (B) ORF2-expressing (lanes 1 and 2) or mock (lanes
3 and 4) cell lysates processed simultaneously and immunoprecipitated with anticalnexin (upper panel) or anti-PDI (lower panel) antibody.
(C) Huh7 cells were transfected with empty vector (mock, lane 1) or with pSGI ORF2 expression plasmid (lanes 2 to 4). [35S]Cys/Met
promix-labeled cells were harvested, and membrane fraction isolated and immunoprecipitated with anti ORF2 antibody. Equal aliquots of the
sample were treated with trypsin (lane 4) or trypsin and NP-40 (lane 3) or were not treated (lane 2). Samples were resolved by 8% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and bands detected by fluorography.
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glycosylation status of the protein (Fig. 4, lanes 3 and 4). The
fact that tunicamycin was active was reflected by the faster
migration of ORF2 as a single band (lane 3). Similarly, treat-
ment of cells with kifunensine blocked ORF2 dislocation (lane
6). Lanes 1 and 2 of Fig. 4 show control cells that were treated
with vehicle only.
Next, we tested whether ORF2 retrotranslocation is medi-
ated in a p97-dependent manner, which has been shown to be
crucial for retrotranslocation (9, 21). First, we looked for in-
teraction of ORF2 with p97 in a coimmunoprecipitation assay.
Both the full-length ORF2 and KDEL-ORF2 proteins were
able to interact with p97 (Fig. 5A, upper panel, lanes 2 and 3).
The interaction was further confirmed by immunoprecipitation
from an aliquot of the same sample with anti-p97 antibody and
immunoblotting with anti-ORF2 antibody (Fig. 5A, middle
panel). The same blot was stripped and probed with anti-p97 to
check for p97 levels (Fig. 5A, lower panel). Having shown that
p97 can coprecipitate ORF2, we checked whether a dominant
negative mutant of the p97 protein could block ORF2 retro-
translocation. Full-length ORF2 and the KDEL-ORF2 protein
were expressed along with myc-tagged wild-type or dominant
negative p97 (QQ-p97). The appearance of ORF2 in the cyto-
plasm was monitored by pulse-chase analysis as described above.
Cells expressing full-length ORF2 were also treated with monen-
sin to block anterograde transport. As expected, QQ-p97 could
block dislocation of both full-length and KDEL-ORF2 (Fig. 5B,
lanes 4 and 8). Aliquots of the total cell lysate were immuno-
blotted using anti-myc (9E10) antibody to check the expression of
wild-type and dominant negative p97 (data not shown). Hence, it
was confirmed that a fraction of the ORF2 protein was retro-
translocated from the ER to the cytoplasm in a p97-dependent
manner.
Heterologous expression of the ORF2 protein upregulates
the expression of ER chaperones. Most of the proteins that are
misfolded, leading to induction of ER stress, are destined for
degradation by the retrotranslocation pathway so as to maintain
ER homeostasis. Since the ORF2 protein was observed to behave
as a substrate of the retrotranslocation pathway, we checked
whether it induces ER stress by monitoring the level of different
ER stress-inducible chaperones. First, we conducted a chloram-
phenicol acetyltransferase (CAT) reporter assay to measure the
promoter activity of an ER stress-inducible chaperone, GRP94, in
ORF2-expressing cells. As expected, ORF2 expression resulted in
upregulation of GRP94 promoter activity (Fig. 6A). Cyclohexi-
mide and tunicamycin were used as negative and positive controls
for this experiment, respectively. Next, we tested the protein level
of GRP94 by immunoblot analysis. There was an increase in the
corresponding protein level in ORF2-expressing cells (Fig. 6B,
top panel). We also tested the protein levels of other chaperones,
i.e., PDI and calnexin. The PDI level was upregulated in ORF2-
expressing cells (Fig. 6B). An aliquot of the cell lysate was immu-
noblotted with antiactin antibody as a loading control (Fig. 6B).
The bottom panel of Fig. 6B shows the expression of ORF2 in the
cell lysate. These experiments suggested that the ORF2 protein
induced ER stress. Therefore, we conclude that the ORF2 pro-
FIG. 3. The ORF2 protein is not a substrate of proteasome and is not ubiquitinated. (A) ORF2-expressing cells were pulse-labeled for 20 min
with [35S]Cys/Met promix, chased for the indicated time period in complete medium, and immunoprecipitated with anti-ORF2 antibody, and
radioactive bands were visualized by fluorography. Band intensities were quantified using the NIH Image program and plotted. The band intensity
at time zero was treated as 100%. (B) ORF2-expressing cells were pulse-labeled for 20 min with [35S]Cys/Met promix, chased for 8 h in complete
medium in the presence of the indicated inhibitor, and immunoprecipitated with anti-ORF2 antibody, and radioactive bands were visualized by
fluorography. Band intensities were quantified using the NIH Image program and plotted. Data represent means  standard errors of the means
from three independent sets of experiments. (C) [35S]Cys/Met promix-labeled mock (lane 1) or ORF2 (lanes 2 and 4)-expressing cells were
immunoprecipitated (IP) with anti-ORF2 antibody and immunoblotted (WB) with antiubiquitin antibody. Bands were detected by the ECL
method. Lane 3 represents total cell lysate. All samples were maintained with MG132 for 3 h prior to lysis. PS, preimmune serum-immunopre-
cipitated sample. The lower panel shows ORF2 expression in the same gel.
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tein induces ER stress and mimics a substrate of the retro-
translocation pathway to gain access to the cytoplasm.
DISCUSSION
The present study uncovers another interesting mode of a viral
protein exploiting the cellular machinery to its benefit. The results
define a possible mechanism by which ORF2 protein localizes to
the cytoplasm despite being an N-linked glycoprotein. HEV is the
causative agent of an acute, self-limiting, and icteric disease that
is prevalent in much of the developing world. Although self-
limiting infection occurs in adults with a mortality rate of 1 to
2%, a high (10 to 20%) mortality rate is observed during preg-
nancy (8). Due to the lack of a small animal model or an efficient
replication-competent cell culture model for the propagation of
HEV, the basic mechanism of pathogenesis mediated by the virus
remains poorly understood. The ORF2 protein has been shown
to be present initially as a glycosylated protein, which gradually
becomes unglycosylated. The majority of this unglycosylated
protein resides in the cytoplasm. Based on its distribution
pattern, earlier studies had suggested that a fraction of the
ORF2 protein is not translocated into the ER (15). However,
that possibility is unlikely, since cotranslational translocation
per se would send ORF2 protein into the ER compartment
even before the complete protein is synthesized. Moreover,
our membrane fractionation study has shown that initially all
the ORF2 protein is localized in the membrane fraction only.
Even if we presume that under our experimental setup, some
undetectable amount of ORF2 does not enter the ER, there is
a very clear increase in the band intensity of cytoplasmic ORF2
protein after 2-h and 4-h chase periods, and this increase
coincides with a decrease in the band intensity of ORF2
present in the membrane fraction. Thus, clearly some fraction
of ORF2 protein is being retrotranslocated from the ER.
Hence, a more feasible hypothesis could be that the ORF2
protein accumulates in the ER and induces ER stress, which
activates the cellular quality control mechanism to remove it
from the ER by the retrotranslocation pathway. Accordingly,
the levels of the ER chaperones were found to be upregulated
in ORF2-expressing cells. Upregulation of the HSP70 (e.g.,
GRP78) and HSP90 (e.g., GRP94) family of chaperones is
known to be associated with the response of unfolded protein,
which binds to and retains the misfolded protein in the ER.
This in turn releases their interaction with ATF6, which sub-
sequently is cleaved to produce the active form of the tran-
scription factor ATF6, which transmits the stress signal to the
nucleus (22). This leads to the activation of ATF6-responsive
promoters such as the GRP94 promoter. Thus, upregulation of
GRP94-CAT activity in ORF2-expressing cells indicates that
the ORF2 protein induces ER stress. Upregulation of PDI
levels suggests that the ORF2 protein is misfolded in the ER.
An increased PDI level may help ORF2 to attain the proper
conformation by rearrangement of disulfide bonding. Alterna-
tively, it may also be possible that ORF2 exploits PDI activity
to become unfolded so as to be retrotranslocated, as has been
demonstrated for cholera toxin (16).
ORF2 was found to follow the retrotranslocation pathway as
judged by its inability to dislocate in the presence of a bio-
chemical inhibitor of mannosidase I and a dominant negative
mutant of p97. However, the property that was peculiar to
ORF2 was its ability to avoid proteasomal degradation in the
cytoplasm, since deglycosylated ORF2 could be readily de-
tected in the cytosolic fraction. This may be due to the fact that
the ORF2 protein was not ubiquitinated and hence was not a
target of the proteasome (however, proteasomal degradation
may also occur in the absence of ubiquitination). Alternatively,
it may be possible that after being retrotranslocated, the ORF2
protein promptly refolds into such a conformation that the
protease-sensitive or ubiquitination sites are masked. The pro-
FIG. 4. Biochemical inhibitors of the ERAD pathway block ORF2
retrotranslocation. Full-length ORF2-expressing cells were pulse-chased
for 2 h in the presence of vehicle only (lanes 1 and 2) or the indicated
inhibitor. Membrane (M) and cytoplasmic (C) fractions were isolated and
immunoprecipitated with anti-ORF2 antibody, and radioactive bands
were visualized by fluorography. The star denotes a nonspecific band
pulled down by protein A-Sepharose.
FIG. 5. ORF2 retrotranslocation is dependent on p97 activity.
(A) Full-length ORF2- or KDEL-ORF2-expressing cell lysate (lanes 1,
2 and 3) or control cell lysate (lane 4) was immunoprecipitated with
preimmune serum (PS) (lane 1), anti-ORF2 antibody (lanes 2 and 3),
or anti-p97 antibody (lane 4) and immunoblotted with anti-p97 anti-
body (upper panel). Mock (lane 1)-, ORF2 (lanes 2 and 4)-, or KDEL-
ORF2 (lane 3)-transfected cells were immunoprecipitated with anti-
p97 antibody (lanes 1, 2, and 3) or anti-ORF2 antibody (lane 4) and
immunoblotted with anti-ORF2 antibody (middle panel). The same
blot was stripped and probed with anti-p97 antibody (lower panel).
(B) Huh7 cells were cotransfected with plasmids expressing full-length
(fl) ORF2 or KDEL-ORF2 and wild-type p97 (WT P97) or mutant P97
(QQ P97) and pulse-chased for 2 h in the presence or absence of
monensin as indicated. Membrane (M) and cytoplasmic (C) fractions
were immunoprecipitated with anti-ORF2 antibody, and the radioac-
tive bands were visualized by fluorography.
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tease-resistant property of the ORF2 protein has been de-
scribed earlier, where in vitro-expressed ORF2 protein was
found to be partially trypsin resistant despite having 50 trypsin
cleavage sites (23). Our data also show that the ORF2 protein
is a substrate of the lysosomal proteases. Further experiments
need to be done to explain this process.
The ability of ORF2 to retrotranslocate was found to be
dependent on its glycosylation status. The ORF2 protein bears
three N-linked glycosylation sites at amino acid residues 137,
310, and 562 (23). Although these sites along with the signal
sequence are conserved in all isolates of human as well as
swine HEV, no functional significance of ORF2 glycosylation
is yet defined. Based on our observation that glycosylation is an
absolute requirement for cytoplasmic localization of wild-type
ORF2, it is tempting to speculate that the observed phenom-
enon will have significance during the natural course of infec-
tion. However, further experiments using a model infection
system need to be carried out to understand the actual phe-
nomenon. Nevertheless, this study provides important insight
into a unique property of the ORF2 protein.
ACKNOWLEDGMENTS
We are thankful to Tom A. Rapoport for providing various p97
constructs, as mentioned in Materials and Methods.
M.S. is supported by a research fellowship from the Council of
Scientific and Industrial Research (CSIR), India. S.J. is an interna-
tional senior research fellow of The Wellcome Trust. This work was
supported by internal funds from ICGEB.
REFERENCES
1. Afshar, N., B. E. Black, and B. M. Paschal. 2005. Retrotranslocation of the
chaperone calreticulin from the endoplasmic reticulum lumen to the cytosol.
Mol. Cell. Biol. 25:8844–8853.
2. Hammond, C., and A. Helenius. 1995. Quality control in the secretory path-
way. Curr. Opin. Cell Biol. 7:523–529.
3. Hazes, B., and R. J. Read. 1997. Accumulating evidence suggests that several
AB-toxins subvert the endoplasmic reticulum-associated protein degradation
pathway to enter target cells. Biochemistry 36:11051–11054.
4. Jameel, S., M. Zafrullah, M. H. Ozdener, and S. K. Panda. 1996. Expression
in animal cells and characterization of the hepatitis E virus structural pro-
teins. J. Virol. 70:207–216.
5. Kar-Roy, A., H. Korkaya, R. Oberoi, S. K. Lal, and S. Jameel. 2004. The
hepatitis E virus open reading frame 3 protein activates ERK through bind-
ing and inhibition of the MAPK phosphatase. J. Biol. Chem. 279:28345–
28357.
6. Kopito, R. R. 1997. ER quality control: the cytoplasmic connection. Cell
88:427–430.
7. Korkaya, H., S. Jameel, D. Gupta, S. Tyagi, R. Kumar, M. Zafrullah, M.
Mazumdar, S. K. Lal, L. Xiaofang, D. Sehgal, S. R. Das, and D. Sahal. 2001.
The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and
activates MAPK. J. Biol. Chem. 276:42389–42400.
8. Panda, S. K., and S. Jameel. 1997. Hepatitis E virus: from epidemiology to
molecular biology. Viral Hepatitis Rev. 3:227–251.
9. Rabinovich, E., A. Kerem, K. U. Frohlich, N. Diamant, and S. Bar-Nun.
2002. AAA-ATPase p97/Cdc48p, a cytosolic chaperone required for endo-
plasmic reticulum-associated protein degradation. Mol. Cell. Biol. 22:626–
634.
10. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a
laboratory manual, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring
Harbor, NY.
11. Simpson, J. C., L. M. Roberts, K. Ro¨misch, J. Davey, D. H. Wolf, and J. M.
Lord. 1999. Ricin A chain utilises the endoplasmic reticulum-associated
protein degradation pathway to enter the cytosol of yeast. FEBS Lett. 459:
80–84.
12. Surjit, M., R. Kumar, R. N. Mishra, M. K. Reddy, V. T. Chow, and S. K. Lal.
2005. The severe acute respiratory syndrome coronavirus nucleocapsid pro-
tein is phosphorylated and localizes in the cytoplasm by 14-3-3-mediated
translocation. J. Virol. 79:11476–11486.
13. Surjit, M., B. Liu, S. Jameel, V. T. Chow, and S. K. Lal. 2004. The SARS
coronavirus nucleocapsid protein induces actin reorganization and apoptosis
in COS-1 cells in the absence of growth factors. Biochem. J. 383:13–18.
14. Surjit, M., R. Oberoi, R. Kumar, and S. K. Lal. 2006. Enhanced alpha1
microglobulin secretion from hepatitis E virus ORF3-expressing human hep-
atoma cells is mediated by the tumor susceptibility gene 101. J. Biol. Chem.
281:8135–8142.
15. Torresi, J., F. Li, S. A. Locamini, and D. A. Anderson. 1999. Only the
non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2)
protein is stable in mammalian cells. J. Gen. Virol. 80:1185–1188.
16. Tsai, B., C. Rodighiero, W. I. Lencer, and T. A. Rapoport. 2001. Protein
disulfide isomerase acts as a redox-dependent chaperone to unfold cholera
toxin. Cell 104:937–948.
17. Tsai, B., Y. Ye, and T. A. Rapoport. 2002. Retrotranslocation of proteins
from the endoplasmic reticulum into the cytosol. Nat Rev. Mol. Cell. Biol.
3:246–255.
18. Tyagi, S., M. Surjit, A. K. Roy, S. Jameel, and S. K. Lal. 2004. The ORF3
protein of hepatitis E virus interacts with liver-specific alpha1-micro-
globulin and its precursor alpha1-microglobulin/bikunin precursor
(AMBP) and expedites their export from the hepatocyte. J. Biol. Chem.
279:29308–29319.
FIG. 6. Heterologous expression of ORF2 protein induces ER
stress. (A) Huh7 cells were transfected in duplicate with the GRP 94
reporter construct alone or with full-length ORF2 or ORF3 expression
constructs (pSGI ORF3 and pSGI ORF2, respectively), and CAT
activity was assayed by measuring acetylation of [14C]chloramphenicol.
The DNA amount was equalized for all samples with empty vector
DNA. CAT activity was quantified and plotted, assuming the highest
activity as being 100%. Data represent means  standard errors of the
means from three independent sets of experiments. Cycloheximide
(CHX)- and tunicamycin (TUN)-treated samples were used as nega-
tive and positive controls, respectively. (B) Huh7 cells were transfected
with empty vector (lane 1) or with pSGI ORF2 expression plasmid
(lane 2). Cells were labeled with [35S]Cys/Met promix and harvested at
48 h posttransfection. Aliquots of the lysate were immunoblotted with
GRP 94, PDI, calnexin, and actin antibodies. An aliquot of the sample
was immunoprecipitated with ORF2 antibody to check the expression
of ORF2 protein by fluorography.
3344 SURJIT ET AL. J. VIROL.
19. Wiertz, E. J. H., T. R. Jones, L. Sun, M. Boygo, H. J. Geuze, and H. L.
Ploegh. 1996. The human cytomegalovirus US11 gene product dislocates
MHC class I heavy chains from the endoplasmic reticulum to the cytosol.
Cell 84:769–779.
20. Wiertz, E. J. H., D. Tortorella, M. Boygo, J. Yu, W. Mothes, T. R. Jones, T. A.
Rapoport, and H. L. Ploegh. 1996. Sec61-mediated transfer of a membrane
protein from the endoplasmic reticulum to the proteasome for destruction.
Nature 384:432–438.
21. Ye, Y., H. H. Meyer, and T. A. Rapoport. 2001. The AAA ATPase Cdc48/p97
and its partners transport proteins from the ER into the cytosol. Nature
414:652–656.
22. Yoshida, H., T. Okada, K. Haze, H. Yanagi, T. Yura, M. Negishi, and K.
Mori. 2000. ATF6 activated by proteolysis binds in the presence of NF-Y
(CBF) directly to the cis-acting element responsible for the mammalian
unfolded protein response. Mol. Cell. Biol. 20:6755–6767.
23. Zafrullah, M., M. H. Ozdener, R. Kumar, S. K. Panda, and S. Jameel. 1999.
Mutational analysis of glycosylation, membrane translocation, and cell surface
expression of the hepatitis E virus ORF2 protein. J. Virol. 73:4074–4082.
VOL. 81, 2007 HEV ORF2 PROTEIN RETROTRANSLOCATES FROM THE ER 3345
